ALLOGENE THERAPEUTICS INC (ALLO)
NASDAQ • Healthcare
Last close at August 10, 2026 at 20:00 UTC
Fundamentals Charts
About ALLOGENE THERAPEUTICS INC
Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage biotechnology company focused on immuno-oncology, developing genetically engineered allogeneic T-cell therapies for cancer. In qualitative terms, it is an early-stage biotech built around off-the-shelf cell therapy candidates for hematologic and solid tumors rather than marketed products.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
ALLOGENE THERAPEUTICS INC's Technical Indicators Summary
ALLO’s technical picture favors a buy stance driven by strong short-term moving averages and bullish breadth in momentum indicators, including an elevated CCI and a positive MACD reading, even as the RSI remains steady in neutral territory. Trend strength is subdued by the ADX, yet on-balance volume is robust and classic pivots sit near the current price, lending support. Volatility is notable at roughly a mid-single-digit percent ATR, which may amplify near-term swings. Technical takeaway: constructive short- to medium-term setup backed by volume and momentum, with modest trend confirmation needed.
| Indicator | Value |
|---|---|
RSI (14) | 60.54 |
Stochastic %K (14, 3, 3) | 95.85 |
CCI (20) | 190.45 |
WPR (14) | 0.00 |
Momentum (10) | 0.35 |
MFI | 64.33 |
MACD Level (12, 26) | 0.01 |
Bollinger Bands | $1.65 - $2.07 |
ATR (14) | $0.12 (5.59%) |
ADX (14) | 17.05 |
OBV | 138,729,048 |
Classic Pivot Point | $2.00 |
Fibonacci Pivot Point | $2.00 |
Simple Moving Averages | $1.86 - $2.13(5 indicators) |
Exponential Moving Averages | $1.79 - $1.99(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Momentum strengthened in the last session as ALLO climbed 4.48% by the closing bell. ALLO faces an earnings preview with consensus for a 17-cent loss per share, per TradingView.
Trading Volume
Below 10d avg (6.8M)
5.3M
vs S&P 500 Today
Strong Outperformance
+4.54%
52-Week Position
Lower range
32%
Updated: August 11, 2026 at 12:19 UTC
Quote Summary
ALLO Headlines
Biotech, Pharma Stocks Draw Fresh Valuation Focus
April 2, 2026